GeoVax's CM04S1 COVID-19 Vaccine Shows Promising Results in Immunocompromised Patients

GeoVax Labs, Inc. will present at the Emerging Growth Conference on September 25, 2025, highlighting recent positive interim clinical results for its lead COVID-19 vaccine candidate, GEO-CM04S1. The presentation will focus on data from two major international scientific meetings that demonstrate the vaccine's effectiveness in immunocompromised patient populations.

Phase 2 data presented at the International Workshop on Chronic Lymphocytic Leukemia 2025 in Krakow, Poland, showed that CM04S1 achieved the study's immune response primary endpoint in chronic lymphocytic leukemia patients, while the comparator mRNA vaccine did not. Based on the Data Safety Monitoring Board recommendation, further enrollment is proceeding exclusively in the CM04S1 arm, indicating strong confidence in the vaccine's performance.

Interim results presented at the European Society of Clinical Microbiology and Infectious Disease 2025 in Lisbon, Portugal, demonstrated robust, durable T-cell and cross-variant antibody responses in immunocompromised blood cancer and post-transplant patients. Notably, no serious adverse events were reported, reinforcing CM04S1's safety profile and differentiation versus standard-of-care vaccines.

David Dodd, Chairman and CEO of GeoVax, stated that these results underscore the promise of CM04S1 as a multi-antigen solution for patients left behind by first-generation COVID-19 vaccines. The company's MVA platform is demonstrating the potential to deliver broad, durable immune protection where it is needed most, particularly for vulnerable populations who may not respond adequately to current vaccine options.

The Emerging Growth Conference presentation will provide investors and stakeholders an opportunity to hear directly from company leadership and participate in a real-time Q&A session. Participants may submit questions in advance to Questions@EmergingGrowth.com or ask them live during the presentation. A replay will be made available following the event on https://www.EmergingGrowth.com and the Emerging Growth YouTube channel at https://www.YouTube.com/EmergingGrowthConference.

This development is significant for the healthcare industry and immunocompromised patients worldwide, as it addresses a critical gap in COVID-19 protection. Current mRNA vaccines have shown limitations in providing adequate immune responses for certain patient populations, particularly those with compromised immune systems due to cancer treatments, organ transplants, or other conditions. The success of CM04S1 could lead to more effective protection for these vulnerable groups, potentially reducing severe COVID-19 outcomes and hospitalizations.

The multi-antigen approach of CM04S1 represents an important advancement in vaccine technology, potentially offering broader protection against emerging variants and more durable immunity. This could have significant implications for public health strategies and pandemic preparedness, particularly for protecting the most vulnerable members of society who remain at elevated risk despite widespread vaccination efforts.